Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias

Cro, Lilla; Guffanti, Andrea; Colombi, M.; Cesana, Bruno Mario; Grimoldi, Maria Grazia; Patriarca, Carlo; Goldaniga, Maria; Neri, Antonino; Intini, Daniela; Cortelezzi, Agostino; At, Maiolo; Baldini, Luca

doi:10.1038/sj.leu.2402737

Cited by 22 publications

(19 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,8 Flow cytometric immunophenotyping (FCI) aids in the differentiation of CLL from MCL. The classic CLL immunophenotype is CD5+, CD20 dim , surface immunoglobulin (sIg) dim , CD23+, and FMC7-, 3,4,9,10 whereas MCL is typically CD5+, CD20 bright , sIg bright , CD23-, and FMC7+. 3,4,9,10 However, ambiguous or overlapping phenotypes have been described.…”

Section: Flow Cytometric Immunophenotyping (Fci) Aids In the Differenmentioning

confidence: 99%

See 1 more Smart Citation

The Role of CD11c Expression in the Diagnosis of Mantle Cell Lymphoma

et al. 2010

View full text Add to dashboard Cite

Flow cytometric immunophenotyping (FCI) aids in the differentiation of chronic lymphocytic leukemia (CLL) from mantle cell lymphoma (MCL); however, overlapping phenotypes may occur. CD11c expression has been reported in up to 90% of CLL cases but has rarely been reported in MCL. Whether CD11c can be used to exclude MCL has not been directly addressed. FCI reports were reviewed for 90 MCL cases (44 patients) and 355 CLL/small lymphocytic lymphoma (SLL) cases (158 patients). MCL cases were confirmed by cyclin D1 immunoreactivity and/or t(11;14) detection by karyotyping or fluorescence in situ hybridization. Cases with typical MCL immunophenotypes did not express CD11c. The 2 MCL cases displaying dim CD11c positivity (2 of 44 patients) expressed other markers not typical of MCL. CD11c was detected in 96 (27.0%) of 355 cases of CLL/SLL representing 53 of 158 patients. CD11c expression is rare in MCL and may aid in differentiation of CD5+ B-cell neoplasms, particularly when small samples limit further ancillary testing.

show abstract

Section: Flow Cytometric Immunophenotyping (Fci) Aids In the Differenmentioning

confidence: 99%

“…The classic CLL immunophenotype is CD5+, CD20 dim , surface immunoglobulin (sIg) dim , CD23+, and FMC7-, 3,4,9,10 whereas MCL is typically CD5+, CD20 bright , sIg bright , and FMC7+. 3,4,9,10 …”

Section: Introductionmentioning

confidence: 99%

The Role of CD11c Expression in the Diagnosis of Mantle Cell Lymphoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The most common CD5-positive lymphomas, both frequently associated with leukaemic blood count, are chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) [1]. Distinction of MCL and CLL is important because of the differences in their clinical behaviour and the therapy they require [2]. Differential diagnosis of the two diseases is typically based on flow cytometric analysis of the leukaemic cell population.…”

Section: Introductionmentioning

confidence: 99%

The cut‐off levels of CD23 expression in the differential diagnosis of MCL and CLL

Barna

Reiniger

Tátrai

et al. 2008

Hematological Oncology

View full text Add to dashboard Cite

Flow cytometric analysis of CD23 expression in CD5-positive B-cells is a widely applied method in the differential diagnosis of chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). According to the most accepted criteria, the leukaemic cell population is CD19/CD5/CD23 triple positive in CLL but CD23-negative in MCL. Recently, several groups have reported CD23-positive MCL cases; however, these studies mostly analysed only CD23 positivity but not intensity. To determine the role and the cut-off levels of CD23 positivity and intensity in the differential diagnosis of CLL and MCL, 26 cases of MCL and 84 cases of CLL were compared using flow cytometric analysis. Our results suggest that high values of CD23 positivity (>92.5%) and/or high fluorescence intensity (>44.5 mean fluorescence intensity (MFI)) of CD23 are related to CLL, whereas low CD23 positivity (<30%) is related to MCL. However, cases with intermediate CD23 positivity (between 30 and 92.5%) and lower intensity (<44.5 MFI) can either belong to CLL or MCL. In these cases, additional tests such as FISH analysis of the translocation t(11;14) or immunohistochemical detection of cyclin D1 overexpression are required to differentiate CLL from MCL.

show abstract

“…The presence of these cases implies that the REAL/WHO classification is not sufficient to classify diverse mature B-cell lymphoid malignancies. Recently, clusters of cases between typical CLL and MCL were reported based on flow cytometry, and they were found to be correlated with prognosis (13). Thus, an additional study should contribute to our understanding of mature B-cell lymphoid malignancies.…”

Section: Discussionmentioning

confidence: 99%

De novo CD5 Positive Diffuse Large B-cell Lymphomas with Bone Marrow Involvement in Korean

et al. 2004

View full text Add to dashboard Cite

In CD5 positive (CD5+) mature B-cell lymphomas, newly recognized CD5+ diffuse large B-cell lymphoma (DLBCL) has been characterized by aggressive features. We studied twenty-five cases with CD5+ lymphomas involving bone marrow. Eleven cases were diagnosed as chronic lymphocytic leukemia, six cases were diagnosed as mantle cell lymphoma (MCL), and three cases with morphologic characteristics of MCL and without both the cyclin D1 expression and IGH/CCND1 rearrangement were unclassifiable. The remaining five cases, showing large to medium-sized lym-phoid cells with prominent nucleoli and a moderate amount of cytoplasm, were diagnosed as DLBCL. Five DLBCL cases were positive for CD5, CD20, surface immuno-globulin, but negative for CD23. Patients with CD5+ DLBCL showed a high age of onset (median, 68 yr) and two patients expired one month after the diagnosis. Since CD5+ DLBCL forms a distinct subgroup of DLBCL, a study of CD5 expression in DLBCL would be helpful to predict prognosis and to determine future therapeutic strategy. To the best of our knowledge, this is the first report on de novo CD5+ DLBCL in Koreans.

show abstract

Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias

Cited by 22 publications

References 19 publications

The Role of CD11c Expression in the Diagnosis of Mantle Cell Lymphoma

The Role of CD11c Expression in the Diagnosis of Mantle Cell Lymphoma

The cut‐off levels of CD23 expression in the differential diagnosis of MCL and CLL

De novo CD5 Positive Diffuse Large B-cell Lymphomas with Bone Marrow Involvement in Korean

Contact Info

Product

Resources

About